Observational study finds 24% lower dementia risk in older adults using osteoporosis treatments — Evidence Review
Published in Alzheimer's & Dementia, by researchers from University of Hong Kong
Researched by
— the AI search engine for science
Table of Contents
A large study suggests that commonly used osteoporosis drugs, specifically nitrogen-containing bisphosphonates (NBPs), are associated with a lower risk of developing Alzheimer's disease and related dementias in older adults. Most related research supports the existence of a link between osteoporosis and increased dementia risk, and some prior studies also indicate that bisphosphonates may help reduce this risk, in line with the new findings published in Alzheimer's & Dementia.
- Multiple studies have found that osteoporosis itself is an independent risk factor for dementia, and that bisphosphonate or estrogen treatment may lower this risk among osteoporosis patients 1 11. The new Hong Kong study extends this by comparing NBPs to other osteoporosis drugs and to untreated patients, finding a greater reduction in dementia risk among NBP users 5.
- Literature reviews highlight complex, bi-directional associations between bone health and cognitive decline, with overlapping risk factors such as age, physical inactivity, and nutritional status 3 4 12. The new study’s findings are consistent with this broader understanding of shared biological pathways.
- Some previous research cautions that people with dementia may receive less osteoporosis treatment, suggesting that interventions targeting both bone and brain health could help reduce morbidity and mortality in aging populations 2 3 4.
Study Overview and Key Findings
Dementia and osteoporosis are two major, interrelated public health concerns among older adults. With the global prevalence of dementia rising rapidly, affordable strategies to prevent or delay its onset are urgently needed. The current study explores whether osteoporosis treatments, specifically nitrogen-containing bisphosphonates (NBPs), could serve a dual purpose: reducing the risk of both fractures and dementia. This approach is especially timely given the high costs and limited access associated with recently approved dementia medications, and the need to optimize existing therapies for additional benefits.
The study analyzed electronic health records from over 120,000 older adults in Hong Kong with osteoporosis or fragility fractures, comparing dementia risk between those treated with NBPs, those taking other osteoporosis medications, and those untreated. Notably, the study estimated that treating 48 patients with NBPs over five years could prevent one dementia case, highlighting a potential public health impact if causality is confirmed.
| Property | Value |
|---|---|
| Organization | University of Hong Kong |
| Journal Name | Alzheimer's & Dementia |
| Authors | Professor Cheung Ching-lung, Dr Sing Chor-wing, Professor Chan Koon-ho, Dr Patrick Chiu Ka-chun, Professor Kathryn Tan Choon-beng |
| Population | Older adults with osteoporosis or fragility fractures |
| Sample Size | n=120,000 |
| Methods | Observational Study |
| Outcome | Dementia risk associated with osteoporosis treatments |
| Results | Patients taking NBPs had a 24% lower dementia risk. |
Literature Review: Related Studies
To contextualize these findings, we conducted a literature review using the Consensus database, which indexes over 200 million research papers. The following search queries were used to identify relevant literature:
- osteoporosis drugs dementia risk reduction
- non-bisphosphonate osteoporosis medications effects
- dementia risk factors osteoporosis treatment comparison
Summary Table of Key Topics and Findings
| Topic | Key Findings |
|---|---|
| How are osteoporosis and dementia risk related? | - Osteoporosis is associated with a higher risk of dementia and Alzheimer's disease compared to non-osteoporosis controls 1 11. - The relationship is bi-directional: cognitive decline can accelerate bone loss, and fractures can increase subsequent dementia risk 3 12. |
| Do osteoporosis drugs, especially bisphosphonates, reduce dementia risk? | - Bisphosphonate treatment or estrogen supplementation is linked to lower dementia risk among osteoporosis patients 1 5. - The new study finds nitrogen-containing bisphosphonates (NBPs) are associated with up to 24% lower dementia risk compared to other osteoporosis drugs or no treatment 5. |
| Are people with dementia under-treated for osteoporosis? | - People with dementia are less likely to receive osteoporosis drugs, despite being at higher risk for fractures 2. - Challenges in prescribing and adherence may contribute to undertreatment, highlighting a gap in comprehensive care for this population 2 4. |
| What biological or clinical factors link bone health and cognitive decline? | - Shared risk factors include age, sex, low physical activity, and nutritional deficiencies; inflammation and hormonal changes may play a mechanistic role 3 4 12. - Certain genes and molecular pathways are implicated in both bone metabolism and neurodegenerative processes 12. |
How are osteoporosis and dementia risk related?
The literature consistently points to a significant association between osteoporosis and an increased risk of dementia, including Alzheimer's disease. Large cohort studies in Taiwan and Germany have shown that osteoporosis patients have a higher incidence of dementia compared to matched controls, even after adjusting for common risk factors. The relationship appears to be bidirectional, with cognitive decline potentially leading to increased bone loss and fractures, and fractures themselves raising subsequent dementia risk.
- Osteoporosis is an independent risk factor for dementia, with hazard ratios ranging from 1.2 to 1.5 in large-scale studies 1 11.
- Fractures, especially hip fractures, are associated with a higher risk of subsequent cognitive decline and mortality in dementia patients 12.
- The new Hong Kong study further supports this link by focusing on a population already at elevated risk due to osteoporosis or fragility fractures 5.
- Literature reviews emphasize the need to consider both bone and brain health together in aging populations, given their intertwined risk profiles 3 4.
Do osteoporosis drugs, especially bisphosphonates, reduce dementia risk?
Several studies have examined whether osteoporosis medications, and particularly bisphosphonates, could have protective effects beyond bone health. Previous cohort analyses and the current Hong Kong study report that bisphosphonate use is associated with a lower risk of dementia among osteoporosis patients, relative to no treatment or alternative osteoporosis therapies. This effect appears stronger with nitrogen-containing bisphosphonates (NBPs), as highlighted by the new findings.
- Bisphosphonate or estrogen therapy is linked to a significant reduction in dementia risk among osteoporosis patients 1.
- The new study reports a 16–24% lower risk of dementia among NBP users, depending on the comparator group 5.
- These findings suggest the potential for drug repurposing, with NBPs possibly offering neuroprotective benefits in addition to fracture prevention 5.
- However, causality cannot be established from observational data, and randomized controlled trials are needed 1 5.
Are people with dementia under-treated for osteoporosis?
Despite their heightened risk of fractures and osteoporosis, people with dementia are less likely to receive preventive osteoporosis treatments. This undertreatment is documented in population-based studies from Sweden and supported by literature reviews discussing challenges in medication adherence and prescribing decisions for cognitively impaired patients.
- Elderly individuals with dementia are less likely to be prescribed osteoporosis drugs, even when they have a history of fractures 2.
- Potential reasons include concerns about adherence, polypharmacy, and risk of falls associated with other medications 4.
- This gap in care may exacerbate both bone and cognitive health outcomes in this vulnerable group 2 4.
- The new study’s focus on osteoporosis drug users highlights the importance of optimizing treatment strategies for older adults at risk of both conditions 5.
What biological or clinical factors link bone health and cognitive decline?
Underlying biological mechanisms and shared risk factors help explain the observed associations between osteoporosis and dementia. Both conditions increase with age and are influenced by factors such as physical inactivity, hormonal status, nutritional changes, and systemic inflammation. Recent research also implicates specific genes and molecular pathways common to bone and brain health.
- Inflammation, hormonal changes (especially estrogen), and the gut microbiome contribute to both cognitive decline and bone loss 4 12.
- Certain genes involved in neurodegeneration, such as APP, BACE1, and TREM2, also influence bone metabolism 12.
- Nutritional status and physical activity are modifiable factors that may impact both osteoporosis and dementia risk 4.
- Understanding these mechanisms could guide future interventions targeting both skeletal and cognitive health 3 12.
Future Research Questions
While observational studies suggest promising associations between osteoporosis drug use and reduced dementia risk, further research is needed to clarify causality, mechanisms, and clinical implications. Randomized controlled trials, mechanistic studies, and implementation research addressing care gaps are all warranted.
| Research Question | Relevance |
|---|---|
| Do nitrogen-containing bisphosphonates directly prevent Alzheimer's disease or dementia? | Establishing direct causality is essential before recommending NBPs for dementia prevention. Observational studies suggest an association, but randomized controlled trials are needed to determine if NBPs have a neuroprotective effect independent of confounding factors 1 5. |
| What biological mechanisms link osteoporosis treatments to reduced dementia risk? | Understanding the molecular and cellular pathways involved could help identify which patients may benefit most and inform the development of dual-purpose therapies. Current literature highlights shared risk factors and pathways but lacks detailed mechanistic studies 4 12. |
| How do other osteoporosis medications (e.g. denosumab, teriparatide) affect cognitive decline risk? | Most existing research focuses on bisphosphonates; comparative studies are needed to assess whether newer osteoporosis drugs also influence dementia risk. This information would help clinicians select optimal regimens for patients with both osteoporosis and cognitive impairment 5 6 10. |
| Does optimizing osteoporosis treatment in people with early cognitive impairment improve outcomes? | People with cognitive impairment are often undertreated for osteoporosis, despite their higher fracture risk. Interventional studies could determine whether targeted osteoporosis management improves both bone health and cognitive outcomes in this population 2 4. |
| What are the long-term risks and benefits of using bisphosphonates in older adults for brain health? | While bisphosphonates are generally safe, their long-term use carries potential risks. Evaluating the balance of benefits and harms, particularly in frail older adults, is necessary for informing clinical guidelines 6 9. |
In summary, the new findings from Hong Kong add to a growing body of evidence suggesting potential cognitive benefits of certain osteoporosis drugs, particularly NBPs, in older adults. While the association is robust in observational data, confirmation through mechanistic studies and randomized controlled trials is needed before clinical practice changes can be recommended. The intersection of bone and brain health remains a promising area for further research and intervention as populations continue to age.